Cosmos Health Inc. (COSM) Stock Price & Analysis

Cosmos Health Inc. (COSM) rose 2.59% to USD 0.27 as of September 8, 2026 at 08:18 UTC, according to Nexqual real-time market data.

COSM last closed at USD 0.27; the session ranged USD 0.26–0.28 on volume of 2,195,642 shares. Market capitalization is —, with a 52-week range of USD 0.16–1.32 (NCM). Source: Nexqual, September 8, 2026 at 08:18 UTC.

Key Statistics (as of September 8, 2026 at 08:18 UTC)

Technical Analysis (COSM)

Nexqual's technical model rates COSM "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 08:18 UTC.

From Cosmos Health Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• We also seek to continually enhance the organizational effectiveness of all of our functions, including efforts to accurately and ethically launch and promote our products.   Information Systems   Our wholesale operations are managed through a primary enterprise resource planning ("ERP") system, which supports key functions including electronic order entry by customers, invoice processing, purchasing, and inventory tracking.
• While nutraceuticals are not classified as drugs, they are often used for their therapeutic effects in a manner similar to pharmaceuticals.   Our proprietary nutraceutical brands are Sky Premium Life® ("SPL") and Mediterranation®.
• Our portfolio currently includes around 165 SKUs and more specifically product codes such as Vitamins and Minerals, Amino Acids, Botanical and other Herbal extracts used for health prevention and care needs.     Our products are classified into two main categories, "Products per Benefit" and "Products per Nutrient" as follows:       Biocides   Our proprietary portfolio of branded biocides and antiseptic soaps comprises of our brands C-Sept® and C-Scrub®.
• Especially for high-cost conditions like cancer, exploring anti-cancer potentials in a vast array of off-patent drugs, which have already established their safety profiles, is a powerful tactic preferred by most leading pharmaceutical enterprises.   We have built on promising preclinical discoveries, predictive insights, and simulations generated by Cosmos Health's AI-powered Cloudscreen® drug repurposing platform.

Partnerships

• GDPR applies to the processing of personal data of persons in the EU by a controller or processor.     Research and Development   The Company entered into a Research & Development agreement with Doc Pharma S.A. on May 17, 2021.
• Thus, no relevant R&D expense had been charged to the Company's Consolidated Statements of Operations and Comprehensive Loss, concerning this agreement.   On June 25, 2022, the Company signed a research and development ("R&D") agreement with a third party (CloudPharm PC), through which the Company assigned to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 08:18 UTC. This page is informational and not investment advice.